Business
Press Release May 20 2026
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 20, 2026, titled "Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors".
About this update from Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 20, 2026, titled "Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors". View Attachment
View stock analysis, news, and events for Glenmark Pharmaceuticals Limited